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Abstract  
Little is known about the clinical relevance of the Montgomery Asberg Depression Rating Scale 
(MADRS) total scores. It is unclear how total scores translate into clinical severity, or how 
commonly used measures for response (reduction from baseline of ≥50% in the total score) 
translate into clinical relevance.  Moreover, MADRS based definitions of remission vary. We 
therefore compared:  a/ the percentage and absolute change in the MADRS total scores with 
Clinical Global Impression – Improvement (CGI-I);  b/ the absolute and percentage change in the 
MADRS total scores with Clinical Global Impression – Severity (CGI-S) absolute change. The 
method used was equipercentile linking of MADRS and CGI ratings from 22 drug trials in 
patients with Major Depressive Disorder (MDD) (n=3,288).  Our results confirm the validity of 
the commonly used measures for response in MDD trials: a CGI-I score of 2 (‘much improved’) 
corresponded to a percentage MADRS reduction from baseline of 48% to 57%, and a CGI-I score 
of 1 (‘very much improved’) to a reduction of 80% to 84%. If a state of almost complete absence 
of symptoms were required for a definition of remission, a MADRS total score would be < 8, 
because such scores corresponded to a CGI-S score of 2 (‘borderline mentally ill’).  
 
Key words: Montgomery Asberg Depression Rating Scale, Clinical Global Impression, 
equipercentile linking 
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Introduction 
The Montgomery Asberg Depression Rating Scale 1 is a 10-item clinician rated instrument 
developed to quantify the severity of depression in subjects already diagnosed with this 
disorder. It is one of the most widely used outcome measure in depression, utilized in many 
trials of new antidepressants submitted to the Food and Drug Administration (FDA) and the 
European Medicines Agency (EMA). Another frequently used clinician rated instrument in 
depression research, the Clinical Global Impressions Scale (CGI) 2, describes a patient’s overall 
clinical state as a global impression. It separates between the patient’s illness severity (CGI-S) 
on a scale from 1 to 7, and change from baseline on an improvement scale (CGI-I, formerly CGI-
Change; details see below). It thus provides information about the clinical relevance of changes 
observed during treatment. It has been shown that CGI appears to be intuitively understood by 
clinicians, achieving good inter-rater reliability3. It has been demonstrated that a substantial 
correlation exists between the MADRS and other frequently used clinician rated  scales used in 
depression, such as the Hamilton Rating Scale for Depression (HAM-D) 4,5, the Global 
Assessment Scale (GAS) 6 or the Beck Depression Inventory 7. While response is usually defined 
as at least 50% reduction of the MADRS total score from baseline, little consensus exists about 
the definition of remission, where cut-offs points of ≤4 8, ≤ 9 8, ≤ 10 9,10, ≤ 12 11, of the MADRS 
have all been used. However, few studies have examined the validity of such cut-off points. 
They remain expert opinion–based definitions, so that an ACNP task force asked for validation 
studies 12. Furthermore, little is known about the clinical relevance of MADRS total scores in 
terms of their correspondence with clinically judged illness severity. In other words, how 
globally ill does a clinician judge someone to be who has a MADRS score of, for example, 20 or 
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30? How much does a clinician really notice a MADRS reduction of, say 50% of the patient’s 
baseline total score? The CGI was designed to give answers to these questions so that we 
decided to use it in an equipercentile linking analysis (see method section13). There is a lot of 
clinical utility in the ability to link such scales, as it allows the nominal translation of vast 
amounts of data into other scales, adding significantly to the available clinical data for various 
treatments without the need for new trials. This has already been shown to be possible and 
useful in the evaluation of clinical relevance of antipsychotics in schizophrenia and 
Transmagnetic Stimulation in major depression.  
 
The purpose of this study was to find corresponding points for simultaneous MADRS and CGI 
ratings within a large sample of patients with Major Depressive Disorder (MDD) who were 
participating in drug trials following the methods of a previous analysis on the relationship 
between the HAMD 4 and the CGI 14.  
 
Materials and methods 
The clinical trial data used for this study come from studies conducted with full sponsorship 
from Organon. Mirtazapine was used as a treatment in placebo controlled, comparator 
controlled or open-label trials in patients with Major Depressive Disorder (MDD). We examined 
absolute as well as percentage reductions from baseline in MADRS total scores and correlated 
them with CGI-Severity of Illness (CGI-S) and CGI-Improvement (CGI-I) scores, using the 
equipercentile linking method 13. This method allows a nominal translation from MADRS scores 
into CGI scores linking the relative values of the two scales. In other words, it gives any 
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particular MADRS total score or percentage change an equivalent value on the CGI-S or CGI-I 
scale.  
 
Rating scales  
The ratings on the MADRS 1 are determined with a semi-structured clinical interview, yielding a 
maximum score of 60. The 10 items are rated on a 0-6 point scale with anchors at 2 points 
intervals. The CGI-S and CGI–I (formerly CGI-C) scales are clinician rated scales 2. For the 
severity scale (CGI-S), clinicians rate patients relative to their past experience with other 
patients with the same diagnosis, with or without collateral information. For the CGI-S, the time 
span considered is the week before the rating, and the following scores can be given: 1=normal, 
not at all ill, 2=borderline mentally ill, 3=mildly ill, 4=moderately ill, 5=markedly ill, 6=severely 
ill, and 7=among the most extremely ill patients. The CGI-I scale assesses the patient’s 
improvement or worsening since the start of the study using the following scores: CGI-I: 1=very 
much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 
6=much worse, 7=very much worse. 
 
The database  
We used individual patient data from all studies assessing the antidepressant mirtazapine 
(tablets and intravenous formulation) in MDD and used MADRS as well as CGI. All those studies 
were sponsored by Organon, now part of Merck (MSD). We only analyzed studies in which 
MADRS and CGI-S and CGI-I assessments were performed at baseline, and days 7, 14 and 28. 
(for an overview of included studies see Table 1). Table 1 about here 
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Statistical analysis 
‘Linking’ pertains to the search for corresponding points on different, but correlated, 
psychometric instruments 13, and is considered as a manner of anchoring that helps in 
understanding the clinical meaning of a given scale score 15,16. It has been previously noted that 
a regression analysis, although frequently used, would not be an appropriate statistical 
approach 15,16, because linear regression treats one scale as the independent variable measured 
without error and the other as the dependent variable measured with error. Thus, this 
approach could be considered conceptually wrong because both variables are actually 
measured with random error. For this study we therefore used equipercentile linking, a 
technique that identifies those scores on both measures that have the same percentile rank. 
This approach was previously used in a number of studies linking the HAM-D 14, and outcome 
measures in schizophrenia and anxiety with the CGI 15-22. The SAS program EQUIPERCENTILE 23 
was used. In the first step, percentile rank functions are calculated for both variables linking is 
performed for. Using the percentile rank function of one variable and the inverse percentile 
rank function of the other, for every score of one variable a score on the other variable that has 
the same percentile rank is identified applying the algorithms described by Kolen and Brennan 
(2004)24. For each linking task, all patients with values which were valid on both measures were 
included in the analysis. The duration of the studies included in our database ranged from 28 to 
156 days (4 to 21 weeks), but not all studies provided data for the same time points. To avoid 
trial effects that could have biased the results, our analysis only included data from baseline 
and Days 7, 14 and 28. The following analyses were performed: 
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a. Linking the MADRS total scores with CGI-S 
b. Linking the absolute and percentage change in the MADRS total scores with CGI-
S absolute change 
c. Linking the percentage and absolute change in the MADRS total scores with CGI-I  
 
Results 
We identified 22 studies (one dose finding study, three placebo controlled studies, four placebo 
and active compound controlled studies, nine direct comparisons between mirtazapine and 
another antidepressant, one double blind oral versus intravenous, and four open-label studies). 
The study data was received courtesy of Organon for the independent use in our group. Our 
database includes all available studies from Organon on mirtazapine. Included patients had a 
diagnosis of a MDD according to Diagnostic and Statistical Manual of Mental Disorders (DSM) 
III, DSM III-R or DSM IV criteria (APA, 1980, 1987, 1994). A total of 3,288 patients participated in 
the examined studies (1,230/37.4% males; 2,057/62.6% females; mean age (standard deviation 
[SD]): 44.9 (13.5) years; mean weight (SD): 70.8 (16.5) kg; mean height (SD): 167.9 (9.5) cm).  
The mean total MADRS score (SD) at baseline was 31.1 (6.5), the mean CGI-S Score (SD) was 4.6 
(1.0); indicative of moderately severe depression and moderate to marked illness severity, 
respectively.  
 
a. The correlations between the MADRS total scores and CGI 
The correlations between the MADRS and CGI are presented in Table 2. The observed 
correlations were statistically significant at all time points (p-value <0.0001) and across all 
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variables analyzed (Spearman correlation between 0.47 and 0.87, Table 2), thus allowing linking 
analysis.   
Table 2 about here 
 
 
b.  Linking of the MADRS total scores with CGI-S 
 
Figure 1 presents the results of the linking between MADRS total scores and CGI-S scores. They 
suggest that a CGI-S score of 1 (‘normal, not at all ill’) corresponds to a MADRS scores of 2 at 
weeks 1, 2, and 4, and of 17 at baseline. CGI-S scores of 2 (‘borderline mentally ill’) 
corresponded to MADRS scores of between 6 and 19; CGI-S scores of 3 (‘mildly ill’) to a MADRS 
scores between 14 and 22; the score 4 (‘moderately ill’) to the scores between 22 and 27, the 
score 5 (‘markedly ill’) to those between 31 to 34, the score 6 (‘severely ill’) to those between 
39 and 40, and the score 7 (‘extremly ill’) to 47-49 and higher. It should be noted that the 
outlier values of the MADRS at baseline (CGI-S scores of not ill, borderline mentally ill and 
mildly ill corresponding to MADRS scores of 17, 19 and 21, respectively) may not be valid. They 
are most likely due to the fact that patients who are currently only mildly depressed are usually 
excluded from such trials. This means that few such patients were available due to minimum 
severity thresholds.  
Figure 1 about here 
 
c. Linking of the percentage change from baseline in the MADRS total scores with the CGI-I 
score 
 
 9 
 
The results were rather consistent across time points analyzed. A CGI-I score of 3 (‘minimally 
improved’) corresponded to a percentage reduction from baseline in the total MADRS score of 
between 21 and 28 %; a CGI-I score of 2 (‘much improved’) corresponded to a reduction of 
between 48 and 57 %; and a CGI-I score of 1 (‘very much improved’) to a reduction of between 
80 and 84 % (Figure 2). 
Figure 2 about here 
 
 
d. Linking of the absolute change in the MADRS total scores with CGI-I scores 
 
The results were consistent for all assessment points examined. A CGI-I score of 4 (‘no change’) 
corresponds with a slight reduction on the MADRS of 1 point. A CGI-I score of 5 (‘minimally 
worse’) corresponded to a minimal increase in the MADRS total score of 4. CGI-I scores of 3 
(‘minimally improved’) corresponded to a reduction of the MADRS of 7-9 points; CGI-scores of 2 
(‘much improved’) corresponded to a reduction on the MADRS by 16-17 points, and a CGI-I 
score of 1 (‘very much improved’) corresponded to a reduction by 27-28 points on the MADRS 
(Figure 3). 
Figure 3 about here  
 
e.   Linking of the absolute change in the MADRS scores with absolute change in the CGI-S 
scores 
Results were consistent across all time points analyzed. A reduction by one severity step on the 
CGI-S corresponded to a reduction of about 8-9 points on the MADRS.  
 
Figure 4 about here 
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Discussion 
Our analysis based on over 3,288 individual patients supports the MADRS criterion for response 
(reduction of at least 50% from baseline on the total MADRS), as a CGI-I score of 2 (‘much 
improved’) corresponded to a reduction from baseline in the total MADRS score of between 48 
and 57%. Moreover, we suggest that in future trials response could be presented in tables of 
25% steps indicating how many patients were unimproved or worse (≤0% MADRS reduction), 
how many had 1- 24% MADRS reduction, 25 to 49% reduction, 50 to 75% reduction and 75-
100% reduction 17. Such tables would show the distribution of response in addition to the 
primary cut-off (≥50%). They fit well to the anchors found by our analysis (CGI-I score of 
‘minimally improved’ (3) = 21 to 28 % MADRS reduction, CGI-I ‘much improved’ (2) = 48 to 57 % 
MADRS reduction; and CGI-I ‘very much improved’ (1) =  80 and 84 % reduction). It also 
corresponds to definitions that describe ≥25% reduction as partial response and ≥50% as 
response 3. 
 
If remission is defined as an (almost) complete absence of illness, a cut-off of ≤ 7 could be used 
because 6-7 points on the MADRS corresponded to a CGI-S score of 2 (‘borderline mentally ill’), 
and a MADRS score of 2 corresponded to a CGI-S score of 1 (‘normal, not at all ill’). These 
results are in line with the findings of Hawley et al. 25 who suggested a cut-off of ≤8/≤9, and 
Zimmerman 8 (≤9), although they who used different methods. Bandelow et al.26 compared the 
MADRS with the CGI in a database of citalopram trials and found that a MADRS score of 11 
corresponded to ‘borderline mentally ill’ on the CGI. As their linking method is not clearly 
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described (it appears that corresponding scores were derived manually rather than with a 
special software), it is difficult to understand the difference, but it is striking that in figures 
showing correlations there is no CGI-S score higher than 5 (see their Figure 4a). The authors 
state that linking results for CGI-S values higher than 4 (moderately ill) could not be provided, 
because too few patients were more than moderately ill. A reason for this might have been the 
exclusion of baseline values, a point in time when many patients are still severely ill. They used 
data of up to 8 weeks, while we restricted our dataset to 4 week results, but they did not find a 
time effect. As their MADRS scores seem to consistently correspond to approximately one CGI 
point higher than ours (e.g. CGI-S of 2 = 11 in their analysis compared to 7 in ours, CGI-S of 3 = 
19 compared to 14 in our analysis), we wonder whether a different coding of CGI scores might 
have occurred. It should be noted that in our analysis - in particular among patients with a CGI 
score of “mildly ill” or even less - the MADRS versus CGI-severity linking analysis at baseline 
deviated from the other weeks. A likely reason for this phenomenon is that due to the studies’ 
inclusion criteria which usually require at least moderately ill patients, few such patients were 
available at baseline. Therefore, the baseline results may not be representative for this 
comparison. 
 
In terms of linking the MADRS absolute change with the CGI-improvement score, on average a 7 
to 9 MADRS points reduction was necessary to be “minimally better”, and an 8 to 9 MADRS 
points change reflected a CGI-severity score reduction of 1 point. These results could be used as 
a proxy for the minimal clinically important change. However, as the results are as a measure of 
reduction from baseline rather than from a difference between mirtazapine and comparators, 
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we would be hesitant to use it as a measure of a minimum clinically important difference 
between treatments.27 
 
Strengths and limitations 
The main strengths of our analysis include that it was based on individual data from a large 
number of patients (>3,000), participating in clinical studies of a single antidepressant 
(mirtazapine), all of whom had the same diagnosis (MDD), while belonging to different patient 
categories (e.g. inpatients, outpatients, patients with melancholia, elderly patients, severely ill 
patients). Thus, the results can be perceived as robust and with solid generalizability. However, 
subjects with dysthymia, non-responsive depression or chronic depression were not included in 
the studies, and the results of a linking analysis including those subjects could have been 
somewhat different.  
 
A potential weakness was the inclusion of open-label and dose-finding studies along with 
double blind comparisons into the study sample. Spielmans  (2006)28 showed that the 
difference between the HAM-D and CGI-S ratings appeared moderated by the degree of trial 
blindness. However, as patients participating in open-label and dose-finding studies of 
mirtazapine represented only 23% of our total sample, it is unlikely that their data could have 
substantially impacted on the overall results. The time effect (different results according to 
time endpoints examined), previously described in a linking analyses of subjects with 
schizophrenia 15,16 was not seen in our analysis except for the baseline deviance of the MADRS 
total and CGI-S results. It is conceivable that clinicians’ expectations of treatment differ in 
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patients with schizophrenia and depression, with clinicians expecting earlier responses from 
antidepressants compared to antipsychotics. No data were available for inter-rater reliability 
across the included studies, all of which could have impacted on the ratings included in the 
analysis. Furthermore, typically at each assessment point the MADRS is the first among the 
assessment scales included in an individual clinical trial report form, thus allowing for the 
possibility that physicians rating the CGI based their judgement on the symptoms that were 
already measured on the MADRS.  
 
In conclusion, despite the methodological limitations, we believe our results will contribute to a 
better understanding and improved interpretation of clinical trial results in MDD.  
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Tables 
Table 1. Summary of mirtazapine MDD studies included in the analysis (possible online 
supplement) 
 
 
Internal 
study 
number/ 
Reference if 
published 
Antidepressive drug 
used 
Sample 
size 
Duration 
(days) Title 
Mean 
MADRS 
score at 
baseline 
003−001 Mirtazapine 12 28 Org 3770 dose−finding study in moderately depressed patients. 32,42 
003−002 Mirtazapine / Placebo 90 42 
A placebo controlled study of Org 
3770 in moderately depressed 
outpatients. 
28,89 
003−003 Mirtazapine / Placebo 90 42 
A placebo−controlled study of Org 
3770 in moderately depressed 
outpatients. 
28,66 
003−008 Mirtazapine / Placebo 150 42 
A controlled dose range study of 
Org 3770 in outpatients with major 
depression. 
27,64 
003−020 
Mirtazapine / 
Amitriptyline / 
Placebo 
130 42 
A controlled study of Org 3770 in 
out−patients with major 
depression. 
27,38 
003−021 
Mirtazapine / 
Amitriptyline / 
Placebo 
150 42 
A controlled study of Org 3770 in 
out−patients with major 
depression. 
29,81 
003−022 
Mirtazapine / 
Amitriptyline / 
Placebo 
150 42 
A controlled study of Org 3770 in 
out−patients with major 
depression. 
37,1 
003−023 Mirtazapine / Trazodone 150 42 
A controlled study of Org 3770 in 
elderly outpatients with major 
depression. 
25,14 
003−024 
Mirtazapine / 
Amitriptyline / 
Placebo 
150 42 A controlled study of Org 3770 in outpatients with major depression. 28,07 
22506 Mirtazapine / Clomipramine 29 42 
An assessor−blind, randomized, 
multicentre, group−comparative 
Clinical Trial of intravenously 
administered Org 3770 and 
Clomipramine in depressed patients 
with a treatment period of 10 days 
followed by a double−blind oral 
treatment period of 32 days. 
34,1 
22519 Mirtazapine / Fluoxetine 131 42+126 
A Multicenter, Open, Randomized, 
Fluoxetine−controlled Study To 
33,69 
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Evaluate Efficacy and Safety of Six 
Weeks Treatment with Oral 
Administration of 30 mg Org 3770 
(Mirtazapine) Once Daily to 
Subjects with Major Depressive 
Disorder 
88013 Mirtazapine / Amitriptyline 115 42 
A multicentre, double−blind, 
randomized, group comparative 
study to evaluate the effects of six 
weeks treatment with Org 3770 and 
amitriptyline administered to 
elderly patients with major 
depressive disorder. 
31,37 
E−1562 Mirtazapine / Citalopram 272 56 
A Multicenter, Double−blind, 
Randomized, Citalopram Controlled 
Efficacy and Safety Study with Org 
3770 in Depressed Subjects. 
29,39 
E−1620 Mirtazapine / Fluoxetine 299 57 
A multicenter, double blind, 
randomized, fluoxetine−controlled 
efficacy 
35,29 
E−1621 Mirtazapine / Venlafaxine 178 57 
A multicenter, double blind, 
randomized, venlafaxine controlled 
efficacy, safety and tolerability 
study (phase IIIb/phase IV) with 
mirtazapine (Org 3770) in severely 
depressed patients with 
melancholic features. 
34,4 
E−1639 Mirtazapine / Paroxetine 62 42 
A single−center, randomized, 
double blind, group comparative 
study on the therapeutic effects of 
six weeks treatment with 
mirtazapine, paroxetine and their 
combination in 60 patients with 
major depression. 
32,87 
E−1690 Mirtazapine / Sertraline 354 56 
A multicenter, double−blind 
randomized sertraline−controlled 
efficacy and safety trial with 
mirtazapine in subjects with a 
major depressive episode 
(according to DSM−IV criteria). 
30,77 
E−1699 Mirtazapine 182 56 
Multicenter randomized 
double−blind comparative groups 
trial in 168 patients with severe 
depression, intended to compare 
the efficacy, safety and 
acceptability of intravenous 
mirtazapine in comparison with 
34,69 
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treatment with oral mirtazapine, 
followed, by 46 days of oral 
treatment 
E−1711 Mirtazapine 103 42 
An open, multicenter trial with 
mirtazapine in moderate to severe 
major depressive episode, assessing 
ist therapeutic efficacy, safety and 
tolerability and exploring clinical 
predictors of therapeutic outcome. 
31,98 
E−1715 Mirtazapine 192 156 
A multi−centre, open−labelled, 
randomised, prospective, clinical 
naturalistic pharmakokinetic and 
pharmacodynamic postmarketing 
surveillance study bsaed on 
Therapeutic Drug monitoring (TDM) 
with mirtazapine in depressed 
patients. 
28,15 
E−1734 Mirtazapine 136 42 
An open−label, multicentre study of 
Mirtazapine in the treatment of 
major depressive episodes. 
29,2 
E−1745 Mirtazapine 163 42 
Efficacy and safety profile of 
Mirtazapine in patients with 
moderate to severe major 
depressive disorder. 
32,83 
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Table 2. Correlations between the MADRS and CGI scores 
Linking 
 
 
Assessment 
 
 
Number of 
Observations 
 
Spearman 
correlation 
coefficient 
P−value 
 
 
MADRS−10 total score vs 
CGI−severity 
 
 
Baseline 3219 0.55 <.0001 
Week 1 2773 0.70 <.0001 
Week 2 2702 0.80 <.0001 
Week 4 2867 0.87 <.0001 
MADRS−10 absolute change vs 
CGI−Severity change 
 
Week 1 2758 0.47 <.0001 
Week 2 2688 0.61 <.0001 
Week 4 2853 0.71 <.0001 
MADRS−10 percent change vs 
CGI−Severity change 
 
Week 1 2758 0.47 <.0001 
Week 2 2688 0.61 <.0001 
Week 4 2853 0.72 <.0001 
MADRS−10 absolute change vs 
CGI−Improvement 
 
Week 1 2578 0.70 <.0001 
Week 2 2524 0.75 <.0001 
Week 4 2692 0.78 <.0001 
MADRS−10 percent change vs 
CGI−Improvement 
 
Week 1 2578 0.73 <.0001 
Week 2 2524 0.79 <.0001 
Week 4 2692 0.84 <.0001 
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Figure legends 
 
Figure 1. Linking of the MADRS total scores and the CGI-S scores  
Figure 2. Linking the percentage change in the MADRS total scores with the CGI-I scores 
Figure 3. Linking the absolute change in the MADRS score with the CGI-I score 
Figure 4. Linking of the absolute changes from baseline in the MADRS and CGI-S scores 
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Figure 1 
 
 
 
 
 
 
 
Figure 2 
 
 
 
 
 
 
Baseline / n=3219 
Week 1 / n=2773 
Week 2 / n=2702 
Week 4 / n=2867 
Week 1 / n=2578 
Week 2 / n=2524 
Week 4 / n=2692 
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Figure 3 
 
 
 
 
 
Figure 4 
 
  
 
 
 
Week 1 / n=2768 
Week 2 / n=2688 
Week 4 / n=2853 
Week 1 / n=2678 
Week 2 / n=2624 
Week 4 / n=2692 
